Nouscom is a next-generation immunotherapy company that is redefining innovation in the field. They specialize in developing genetic cancer vaccines and oncolytic viruses to empower the immune response against tumors. By utilizing their proprietary immunotherapy platforms, which consist of uniquely engineered viral vectors optimized for the expression of tumor neoantigens, Nouscom is able to induce broad and potent anti-tumor T cell responses.

Their approach involves encoding an unprecedented number of tumor neoantigens, allowing for the selective elimination of tumor cells and the enhancement of cancer-specific cellular immunity. They offer both off-the-shelf immunotherapies and personalized neoantigen vaccines tailored to individual patient mutanomes. In addition, Nouscom's pipeline includes a targeted oncolytic virus called Endovax, which can be delivered locally or systemically to treat solid tumors.

Their innovative products and services aim to expand the applicability and efficacy of existing immunotherapies while maintaining high levels of safety and tolerability. With offices, research, and manufacturing facilities in Basel, Switzerland and Rome, Italy, Nouscom is at the forefront of the fight against cancer